Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (Nasdaq: IDYA) announced a business update and financial results for Q2 2021, reporting a net loss of $10.9 million. Cash reserves stood at $312.4 million, bolstered by a recent $86.5 million capital raise. The company highlighted clinical advancements in its synthetic lethality pipeline, including positive preliminary results for IDE397 in MTAP-deletion patients and promising data for darovasertib in metastatic uveal melanoma. IDEAYA aims for FDA guidance on darovasertib monotherapy in H2 2021 and anticipates two potential development candidates in Q4 2021.

IDEAYA Biosciences (NASDAQ: IDYA) will participate in a panel discussion titled "Synthetic Lethal (Weapon)" at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 11:30 am ET. The panel includes industry leaders like Michael Dillon, Chief Scientific Officer at IDEAYA, and Barbara Weber, CEO of Tango Therapeutics. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA is focused on synthetic lethality and targeted therapeutics, integrating biomarker identification with drug discovery.

IDEAYA Biosciences announced the closing of its public offering of 5,333,333 common stock shares at $17.25 each, raising approximately $86.1 million after expenses. The offering included a full exercise of over-allotment, adding 695,652 shares. Proceeds will fund clinical development of IDE397, other product candidates, and ongoing trials for darovasertib in metastatic uveal melanoma. The offering was conducted under an SEC-approved shelf registration. J.P. Morgan, Citigroup, Jefferies, and Guggenheim acted as book-running managers.

IDEAYA Biosciences (NASDAQ:IDYA) has announced a public offering of 4,637,681 shares at a price of $17.25 per share, aimed at raising approximately $80 million before expenses. The underwriters have a 30-day option to purchase an additional 695,652 shares. The funds will support the clinical development of drug candidates, including IDE397 and darovasertib, among other research activities. The offering is expected to close around July 12, 2021, pending customary conditions.

IDEAYA Biosciences (Nasdaq: IDYA) plans to offer and sell up to $80 million in common stock through an underwritten public offering, with an additional $12 million option for underwriters. Proceeds will support clinical development of its MAT2A inhibitor, ongoing research into poly (ADP-ribose) glycohydrolase targets, and further studies on darovasertib for treating metastatic uveal melanoma. The offering is pending market conditions and will be conducted under a shelf registration statement.

IDEAYA Biosciences (Nasdaq:IDYA) announced updates on its Phase 1 clinical trial for IDE397 and the initiation of a Phase 2 trial for darovasertib combination therapies in metastatic uveal melanoma. The early results for IDE397 show a significant reduction in plasma S-adenosyl methionine (SAM), suggesting effective target engagement. The company is expanding its clinical sites and has reported no serious drug-related adverse events. There are also promising early responses in darovasertib trials, including tumor reductions of up to 56.5%.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 2021 Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 pm ET. The conference will feature a fireside chat with Maury Raycroft. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days following the event. IDEAYA focuses on synthetic lethality and precision medicine for oncology, integrating biomarker identification with drug discovery to enhance targeted therapeutics.

IDEAYA Biosciences (Nasdaq:IDYA) reported a business update and financial results for Q1 2021, highlighting development in its clinical trials, especially for IDE397, a MAT2A inhibitor targeting MTAP deletion tumors. The company announced a net loss of $9.0 million compared to $5.1 million in the previous quarter, with cash reserves amounting to $310.4 million. Collaboration revenue decreased to $7.2 million from $10.6 million. IDEAYA also expects to achieve multiple preclinical and clinical milestones across its targeted synthetic lethality programs in 2021 and beyond.

IDEAYA Biosciences (NASDAQ: IDYA) announced the dose expansion of its Phase 1/2 study on the darovasertib and crizotinib combination therapy for metastatic uveal melanoma (MUM). Encouraging early results indicate tumor reduction in two evaluable patients, including a notable 54% reduction in one patient. Despite drug-related adverse events such as syncope and hypotension, the combination therapy shows promise. Further patient enrollment continues as IDEAYA aims to explore additional doses, building on preliminary data and preclinical findings presented at AACR 2021.